|Chemical and physical data|
|Molar mass||369.484 g·mol−1|
|3D model (JSmol)|
TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.
- James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ (February 2020). "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor". Clinical Pharmacology in Drug Development. 9 (2): 256–266. doi:10.1002/cpdd.721. PMID 31286645. S2CID 195843184.